Phase 3 Clinical Trials With Primary Completion Dates in February 2023
This is a list of Phase 3 trials with primary completion dates in February 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ALID||Allied Corp.||2023-02-01||Phase 3||NCT04750070||Management of Shock in Children With SAM or Severe Underweight and Diarrhea|
|ALVO||Alvotech||2023-02-01||Phase 3||NCT05155293||Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)|
|BTAI||BioXcel Therapeutics, Inc.||2023-02-01||Phase 3||NCT05271552||Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)|
|CERE||Cerevel Therapeutics Holdings, Inc.||2023-02-01||Phase 3||NCT04542499||Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations|
|CSTL||Castle Biosciences, Inc.||2023-02-01||Phase 3||NCT04213261||A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa|
|CYDY||CytoDyn Inc.||2023-02-01||Phase 3||NCT04901689||Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation|
|JAZZ||Jazz Pharmaceuticals plc||2023-02-01||Phase 3||NCT04203498||Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis|
|MGCLF||MGC Pharmaceuticals Limited||2023-02-01||Phase 3||NCT04802382||Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19|
|TVTX||Travere Therapeutics, Inc.||2023-02-01||Phase 3||NCT03493685||Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)|
|URGN||UroGen Pharma Ltd.||2023-02-01||Phase 3||NCT05243550||A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer|